Mantle Cell Lymphoma

CAR T-cell therapy is effective and tolerable in patients with mantle cell lymphoma with secondary central nervous system involvement.

Jean L. Koff, MD, MS, discusses key considerations in the choice of BTK inhibitors for frontline and maintenance treatment in MCL.

Acalabrutinib plus bendamustine and rituximab (BR) led to a statistically significant improvement in PFS vs BR for treatment-naive mantle cell lymphoma.

William B. Pearse, MD, discusses the current treatment paradigm for patients with relapsed/refractory mantle cell lymphoma.

Real-world treatment with zanubrutinib was linked to longer treatment persistence, duration, and time to discontinuation in mantle cell lymphoma.

B-cell receptor signaling characteristics were associated with worse outcomes in patients with mantle cell lymphoma.

William B. Pearse, MD, discusses the current role of the BTK inhibitor pirtobrutinib in patients with relapsed/refractory mantle cell lymphoma.

Catherine C. Coombs, MD, discusses the mechanism of action of noncovalent BTK inhibitors in patients with relapsed/refractory mantle cell lymphoma.

CTL019 CAR T-cell therapy plus time-limited ibrutinib resulted in high complete response rates in relapsed/refractory mantle cell lymphoma.

Ibrutinib with or without rituximab was effective and tolerable in patients with previously untreated, low-risk mantle cell lymphoma.

A matching-adjusted indirect comparison shows that brexu-cel is superior to pirtobrutinib regarding response and survival in relapsed/refractory MCL.

TP53 mutation and EZH2 expression negatively affect outcomes in mantle cell lymphoma, with a synergistic negative effect.

The FDA has lifted a partial clinical hold on a phase 1 trial evaluating NX-2127 in relapsed/refractory B-cell malignancies

Andre H. Goy, MD, discusses how the ZUMA-18 trial data support the benefit of earlier-line use of brexucabtagene autoleucel in mantle cell lymphoma.

In case you missed it, read a recap of every episode of OncLive On Air recorded in January 2024.

Liso-cel may be an effective treatment option for patients with relapsed/refractory mantle cell lymphoma and high-risk features.

Catherine C. Coombs, MD, spotlights the use of bispecific antibodies in diffuse large B-cell lymphoma and pirtobrutinib in mantle cell lymphoma.

Jonathon B. Cohen, MD, MS, discusses the background of the BRUIN study of pirtobrutinib in previously treated patients with mantle cell lymphoma.

A panel of experts discuss how to sequence BTK inhibitors and CAR T-cell therapies in patients with MCL.

Experts on mantle cell lymphoma discuss third-line treatment options available for patients.

Andre Goy, MD, discusses the evaluation of brexu-cel in the ZUMA-2 and expanded access ZUMA-18 trials in relapsed/refractory mantle cell lymphoma.

William B. Pearse, MD, discusses unanswered questions regarding the sequencing of pirtobrutinib and other BTK inhibitors in mantle cell lymphoma.

Experts on mantle cell lymphoma discuss second-line treatment options available for patients.

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline MCL.

Jonathon B. Cohen, MD, MS, expands on updated data from the BRUIN trial of pirtobrutinib in patients with relapsed BTK-exposed mantle cell lymphoma.